Sigilon Therapeutics Inc
SGTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$729.54M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $729.54 Million |
|---|---|
| Enterprise Value | $731.09 Million |
| Earnings per Share | $-1.34 |
| Beta | 4.11 |
| Outstanding Shares | 32,467,382 |
Return
| Return on Equity | -107.75% |
|---|---|
| Return on Assets | -53.23% |
| Return on Invested Capital | -100.03% |
Valuation & Multiples
| P/E Ratio | -16.77 |
|---|---|
| PEG | 34.37 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 41.41 |
| Enterprise Value to EBIT | -24.11 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.77 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Sigilon Therapeutics Inc
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial pr...